Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 13, 2026
TickeronGET DAILY SIGNALS
Metagenomi Therapeutics (MGX) Shares Slide -17% Over 30 Days Despite FDA Clearance

Metagenomi Therapeutics (MGX) Shares Slide -17% Over 30 Days Despite FDA Clearance

Key Takeaways

  • MGX shares have fallen roughly 17% over the past 30 days, sliding from about $0.86 in mid-October to near $0.71 and extending a broader multi-month downtrend.
  • The decline pushed the stock below the $1.00 Nasdaq minimum-bid threshold, intensifying investor concerns about a potential reverse split or additional share issuance.
  • Third-quarter results reported in early November showed a widening net loss as collaboration revenue continues to wind down following former partner Moderna (MRNA)'s 2024 exit.
  • Against the weak share price, the company received FDA clearance of its investigational new drug (IND) application for lead candidate MGX-001 in hemophilia A, with a global clinical trial targeted for the first half of 2027.
  • Analysts maintain a broadly positive stance with an average 12-month price target near $7, yet the micro-cap stock trades at a fraction of its cash balance, reflecting market skepticism about a still-preclinical pipeline.
  • Over the last quarter, MGX has fallen roughly 42%, extending a decline from its 52-week high near $3.95.

Metagenomi Therapeutics (MGX) Company Background

Metagenomi Therapeutics, Inc. (MGX) is an in vivo genome editing company headquartered in Emeryville, California, focused on developing curative genetic medicines. The company was founded in 2016 and completed its initial public offering in February 2024 at $15.00 per share. It builds a proprietary, metagenomics-derived toolbox of editing tools, including CRISPR nucleases, base editors, and large-gene integration systems, to correct genetic mutations across the human genome.

The company's lead wholly owned program, MGX-001, is a one-time gene-editing treatment for hemophilia A designed to insert a Factor VIII DNA cassette into the albumin gene, aiming to provide durable protection from bleeding events and joint damage. Metagenomi also maintains a collaboration with Ionis Pharmaceuticals (IONS) across several programs. As a pre-commercial biotech with no approved products, MGX is closely followed for its clinical milestones, cash position, and partnership activity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

MGX Stock Performance Over the Past 30 Days and Quarter

Over the last 30 days, MGX has declined approximately 17%, falling from a closing price of about $0.86 in mid-October to near $0.71. The move accelerated as the stock broke decisively below the $1.00 level, a threshold that carries significance for Nasdaq listing requirements.

The quarterly picture is even steeper. Three months earlier, MGX closed around $1.23 in mid-August, meaning the stock has lost roughly 42% over the quarter. The shares reached an intraday 52-week low of $0.60 in early November, far below their 52-week high near $3.95. This sustained slide reflects persistent selling pressure in a thinly traded, low-float micro-cap name rather than a single sharp event.

Factors Behind the Recent 30-Day Pressure on MGX

Several factors combined to pressure MGX over the past month. First, the stock slipped below the $1.00 level in early-to-mid October and has struggled to reclaim it, raising concerns about Nasdaq minimum-bid compliance and the possibility of a reverse stock split or dilutive financing to address it. Micro-cap biotech names trading near their cash value are especially sensitive to these balance-sheet concerns.

Second, third-quarter results reported in early November showed a net loss of $21.13 million, slightly wider than the prior-year period, with nine-month losses of $71.67 million. Collaboration revenue continues to wind down as legacy partnership programs conclude, leaving the company dependent on its cash reserves, which stood at $120.7 million as of June 30, 2026.

Notably, the negative price action persisted even after positive news: on the same day as earnings, the company announced FDA clearance of its IND application for MGX-001 and plans to begin a global clinical trial in the first half of 2027, with initial data expected in the second half of that year. The muted market response underscores investor caution toward a program that remains preclinical, combined with limited trading liquidity that amplifies day-to-day volatility. From what I see, this disconnect is worth monitoring closely.

Quarterly Decline and Broader Repricing of MGX Shares

The quarterly decline extends a longer-running repricing of the stock. Metagenomi underwent a restructuring in November 2025 that cut roughly a quarter of its workforce, and its chief executive departed, with Jian Irish assuming the role. That transition followed the 2024 wind-down of its collaboration with Moderna, which significantly reduced partnership revenue.

Over the past several months, the market has increasingly priced MGX relative to its cash and near-term funding needs rather than its long-term pipeline potential. With no product revenue, a cash burn in the tens of millions of dollars per quarter, and a lead candidate still years from commercialization, the shares have drifted lower despite a consensus "Strong Buy" rating and an average analyst price target near $7 from five analysts. The disconnect between analyst targets and the market price highlights the speculative nature of the valuation at this stage.

Key Catalysts Ahead for MGX Investors

Looking ahead, the key catalysts for MGX center on clinical execution and capital. Investors are likely to monitor the planned initiation of the MGX-001 global clinical trial in the first half of 2027 and the initial clinical data anticipated in the second half of the year. Funding is equally critical: the company has guided that its cash supports operations into the fourth quarter of 2027, but any financing decisions, share issuance, or reverse-split action tied to Nasdaq compliance could materially affect the stock.

Additional factors to watch include updates on the Ionis collaboration, analyst price-target revisions as the clinical timeline firms up, and broader biotech-sector sentiment. As always, these developments carry risk, and the stock's behavior will depend on whether the company can translate its preclinical promise into clinical data before its cash runway narrows. I’m watching this closely as the timeline firms up.

AI Trading Bots as a Research Complement

In my own analysis of names like MGX, I’ve turned to Tickeron’s AI Trading Bots to test rules-based strategies across different timeframes. The platform offers a range of bots that monitor market signals and can help surface patterns I might otherwise overlook, providing an additional layer of data alongside traditional fundamental review. It’s been a practical way to cross-check sentiment in volatile micro-cap names without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MGX

Contributor

Dem Sem's AvatarDem Sem|Expert

MGX in -8.54% downward trend, sliding for three consecutive days on November 13, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MGX declined for three days, in 158 of 180 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for MGX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 30 cases where MGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.

Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5959 Horton Street
Phone
+1 510 871-4880
Employees
119
Web
https://metagenomi.co
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
EUO is a leveraged inverse currency fund targeting -2x the daily performance of the euro versus the U.S. dollar, while XXX is a passive asset-allocation fund blending roughly 75% S&P 500 equities with 25% XRP exposure. The two funds are structurally unrelated: EUO is a tactical hedging and trading tool, whereas XXX is a diversified, long-biased growth vehicle.
Metagenomi Therapeutics (MGX) Shares Slide -17% Over 30 Days Despite FDA Clearance